Equity Overview
Price & Market Data
Price: $1.43
Daily Change: +$0.0794 / 5.55%
Daily Range: $1.35 - $1.45
Market Cap: $34,102,972
Daily Volume: 103,939
Performance Metrics
1 Week: -2.07%
1 Month: 5.97%
3 Months: 36.54%
6 Months: 37.86%
1 Year: 11.81%
YTD: 21.37%
Company Details
Employees: 36
Sector: Health technology
Industry: Biotechnology
Country:
Details
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.